Search Results - "Goodman, AD"

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate by Ford, C., Goodman, AD, Johnson, K., Kachuck, N., Lindsey, JW, Lisak, R., Luzzio, C., Myers, L., Panitch, H., Preiningerova, J., Pruitt, A., Rose, J., Rus, H., Wolinsky, J.

“…The ongoing US Glatiramer Acetate (GA) Trial is the longest evaluation of continuous immunomodulatory therapy in relapsing—remitting multiple sclerosis (RRMS)…”
Get full text

Human Herpesvirus 6 Genome and Antigen in Acute Multiple Sclerosis Lesions by Goodman, Andrew D, Mock, David J, Powers, James M, Baker, Jeffrey V, Blumberg, Benjamin M

“…Evidence for a candidate multiple sclerosis (MS) virus, human herpesvirus 6 (HHV-6), was sought in biopsy specimens of acute lesions that presented clinically…”
Get full text

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial by Goodman, Andrew D, Prof, Brown, Theodore R, MD, Krupp, Lauren B, MD, Schapiro, Randall T, MD, Schwid, Steven R, MD, Cohen, Ron, MD, Marinucci, Lawrence N, MS, Blight, Andrew R, PhD

“…Summary Background Clinical studies suggested that fampridine (4-aminopyridine) improves motor function in people with multiple sclerosis. This phase III study…”
Get full text

Dose comparison trial of sustained-release fampridine in multiple sclerosis by GOODMAN, A. D, BROWN, T. R, COHEN, J. A, KRUPP, L. B, SCHAPIRO, R, SCHWID, S. R, COHEN, R, MARINUCCI, L. N, BLIGHT, A. R

“…To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS). This multicenter,…”
Get full text

Rapid disease course in African Americans with multiple sclerosis by KISTER, I, CHAMOT, E, JUBELT, B, KRUPP, L, LENIHAN, M, LUBLIN, F, MIHAI, C, MILLER, A, MUNSCHAUER, F. E, PEREL, A. B, TETER, B. E, WEINSTOCK-GUTTMAN, B, BACON, J. H, ZIVADINOV, R, HERBERT, J, NIEWCZYK, P. M, DE GUZMAN, R. A, APATOFF, B, COYLE, P, GOODMAN, A. D, GOTTESMAN, M, GRANGER, C

“…To investigate utility of a Multiple Sclerosis Severity Scale (MSSS)-based classification system for comparing African American (AA) and white American (WA)…”
Get full text

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks by Morrow, SA, O'Connor, PW, Polman, CH, Goodman, AD, Kappos, L, Lublin, FD, Rudick, RA, Jurgensen, S, Paes, D, Forrestal, F, Benedict, RHB

“…Background and Objectives: Brief cognitive tests to monitor cognitive impairment in patients with multiple sclerosis (MS) are needed. Methods: Performance on…”
Get full text

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS by Cohen, J A, Cutter, G R, Fischer, J S, Goodman, A D, Heidenreich, F R, Kooijmans, M F, Sandrock, A W, Rudick, R A, Simon, J H, Simonian, N A, Tsao, E C, Whitaker, J N

“…Interferon beta-1a (IFNbeta-1a, Avonex) is efficacious in relapsing forms of MS. Studies of other IFNbeta preparations in secondary progressive MS (SPMS)…”
Get full text

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS by COHEN, J. A, IMREY, P. B, HUTTON, G. J, MANDELL, B. F, SCOTT, T. F, ZHANG, H, APPERSON-HANSEN, C, BECK, G. J, HOUGHTALING, P. L, KARAFA, M. T, STADTLER, M, CALABRESI, P. A, EDWARDS, K. R, EICKENHORST, T, FELTON, W. L, FISHER, E, FOX, R. J, GOODMAN, A. D, HARA-CLEAVER, C

“…To assess the safety, tolerability, and efficacy of interferon beta-1a (IFNbeta-1a) combined with methotrexate (MTX), i.v. methylprednisolone (IVMP), or both…”
Get full text

Quantitative functional measures in MS: What is a reliable change? by SCHWID, S. R, GOODMAN, A. D, MCDERMOTT, M. P, BEVER, C. F, COOK, S. D

“…As a first step toward understanding which changes should be considered as meaningful, the authors assessed the reliability of quantitative functional tests on…”
Get full text

Fatigue in multiple sclerosis: current understanding and future directions by Schwid, Steven R, Covington, Melissa, Segal, Benjamin M, Goodman, Andrew D

“…Fatigue is a very common symptom of multiple sclerosis (MS). Theoretically, fatigue may be related to neuromodulation by soluble products of the autoimmune…”
Get full text

Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS by COHEN, J. A, ROVARIS, M, GOODMAN, A. D, LADKANI, D, WYNN, D, FILIPPI, M

“…To evaluate the safety, tolerability, and efficacy of glatiramer acetate (GA) 40 mg daily vs the approved 20-mg formulation in relapsing-remitting multiple…”
Get full text

Cognitive fatigue during a test requiring sustained attention: a pilot study by Schwid, Steven R, Tyler, Carolyn M, Scheid, Eileen A, Weinstein, Amy, Goodman, Andrew D, McDermott, Michael P

“…Background: Fatigue is common in multiple sclerosis (MS), but difficulty quantifying fatigue severity has impeded studies of its characteristics, mechanisms,…”
Get full text

Quantitative assessment of motor fatigue and strength in MS by SCHWID, S. R, THORNTON, C. A, PANDYA, S, MANZUR, K. L, SANJAK, M, PETRIE, M. D, MCDERMOTT, M. P, GOODMAN, A. D

“…To determine the test-retest reliability of strength and fatigue measurements in patients with MS and in healthy control subjects, and to examine associations…”
Get full text

Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis by SCHWID, S. R, PETRIE, M. D, MCDERMOTT, M. P, TIERNEY, D. S, MASON, D. H, GOODMAN, A. D

“…To evaluate the efficacy of 4-aminopyridine sustained release (4AP SR) (fampridine, EL-970) using quantitative measures of motor function in multiple sclerosis…”
Get full text

Results of a phase 2, randomized, double-blind, placebo-controlled study by Goodman, AD, Rossman, H, Bar-Or, A, Miller, A, Miller, D H, Schmierer, K, Lublin, F, Khan, O, Bormann, N M, Yang, M, Panzara, MA, Sandrock, A W

“…Objective: To evaluate the safety and tolerability of natalizumab when added to glatiramer acetate (GA) in patients with relapsing multiple sclerosis. The…”
Get full text

Potential Environmental and Host Participants in the Early White Matter Lesion of Adreno-Leukodystrophy: Morphologic Evidence for CD8 Cytotoxic T Cells, Cytolysis of Oligodendrocytes, and CD1-Mediated Lipid Antigen Presentation by ITO, MASUMI, BLUMBERG, BENJAMIN M, MOCK, DAVID J, GOODMAN, ANDREW D, MOSER, ANN B, MOSER, HUGO W, SMITH, KIRBY D, POWERS, JAMES M

“…The 2 most common forms of X-linked adreno-leukodystrophy (ALD) are the juvenile or childhood cerebral form with inflammatory demyelination and the adult…”
Get full text

Sustained-release fampridine consistently improves walking speed and leg strength in multiple sclerosis: a phase 3 trial by Goodman, AD, Schwid, SR, Brown, T R, Krupp, L B, Schapiro, R T, Marinucci, L N, Cohen, R, Blight, A R

“…Background: A prior Phase 3 study of sustained-release fampridine (4-aminopyridine) in MS showed beneficial effects on ambulation and leg strength. Objective:…”
Get full text

An open-label safety and drug interaction study of natalizumab (Antegren™) in combination with interferon-beta (Avonex®) in patients with multiple sclerosis by Vollmer, T L, Phillips, J T, Goodman, A D, Agius, M A, Libonati, M A, Giacchino, J L, Grundy, J S

“…In this open-label drug-interaction trial, we studied 38 patients with relapsing-remitting multiple sclerosis (MS) who received 3.0 or 6.0 mg/kg of natalizumab…”
Get full text

Avonex Combination Trial in relapsing—remitting MS: rationale, design and baseline data by Cohen, JA, Calabresi, PA, Chakraborty, S., Edwards, KR, Eickenhorst, T., Felton, WL, Fisher, E., Fox, RJ, Goodman, AD, Hara-Cleaver, C., Hutton, GJ, Imrey, PB, Ivancic, DM, Mandell, BF, Perryman, JE, Scott, TF, Skaramagas, TT, Zhang, H.

“…Objective To review the rationale, design and baseline data of the Avonex Combination Trial (ACT), an investigator-run study of intramuscular interferon…”
Get full text

Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial by Johnson, K P, Brooks, B R, Ford, C C, Goodman, A D, Lisak, R P, Myers, L W, Pruitt, A A, Rizzo, M A, Rose, J W, Weiner, L P, Wolinsky, J S

“…The aim of this study was to assess the long-term safety and efficacy of glatiramer acetate (GA) for patients with multiple sclerosis (MS) who received active…”
Get full text